The post-MI period is characterized by adverse ventricular remodeling, neurohormonal activation, and heightened cardiorenal vulnerability—pathophysiological processes potentially modifiable by SGLT2 inhibition [36]. This evidence concerns the gene SLC5A2 and myocardial infarction.